Back to search
FDAFDA · Food and drugs·Recall number D-0516-2019

Temozolomide Capsules, 5 mg, packaged in a) 5-count bottle (NDC 43975-252-05) b) 14-count bottle (NDC 43975-252-14), Rx only, Mfd. by: Stason Pharmaceuticals, Inc., Irvine, CA 92618, Dist. By: Amerigen Pharmaceuticals, Lyndhurst, NJ 07071

Published February 27, 2019 · Recall initiated: February 19, 2019

Summary

FDA records drug Class III recall D-0516-2019, published February 27, 2019 and initiated February 19, 2019. Recalling firm: Amerigen Pharmaceuticals Inc.; Status: Terminated; Reported quantity: a) 2,413 bottles b) 3,355 bottles; Lot: Lot #: a) 18J043A, Exp 09/30/2020, b) 18J043B, Exp 09/30/2020. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed dissolution specifications

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Amerigen Pharmaceuticals Inc.
Distributor
Product was distributed to 4 wholesalers/distributors and 1 retail account who may have further distribute the product throughout the United States.
Lot
Lot #: a) 18J043A, Exp 09/30/2020, b) 18J043B, Exp 09/30/2020
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Temozolomide Capsules, 5 mg, packaged in a) 5-count bottle (NDC 43975-252-05) b) 14-count bottle (NDC 43975-252-14), Rx only, Mfd. by: Stason Pharmaceuticals, Inc., Irvine, CA 92618, Dist. By: Amerigen Pharmaceuticals, Lyndhurst, NJ 07071 recalled?

Yes. FDA published recall D-0516-2019 on February 27, 2019. Reported hazard: Failed dissolution specifications

What should I do if I have this product?

Voluntary: Firm initiated · Letter